Under Armour (NYSE: UA) has acquired MapMyFitness, an Austin, Texas-based maker of a fitness-tracking app, for approximately $150 million. MapMyFitness had raised over $20 million in VC funding from firms like Austin Ventures, Milestone Venture Partners, The Running Co. and Competitor Group.Read more
CrowdSource, a Swansea, Ill.-based provider of managed crowdsourcing solutions, has agreed to acquire San Francisco-based rival Servio for an undisclosed amount. CrowdSource has raised VC funding from Highland Capital Partners, while Servio was backed by Draper Fisher Jurvetson.www.crowdsource.com
Textura Corp. (NYSE: TXTR) has agreed to acquire Latista Technologies, a Reston, Va.–based provider of mobile-enabled solutions for construction project collaboration, for $35 million in cash. Sellers include Berman Venture Capital and Blu Venture Investors. www.latista.com
Berkshire Hathaway reported that it has amassed around 40 million shares in Exxon Mobil Corp.(NYSE: XOM) — less than 1% of the oil company’s outstanding shares — which is valued at around $3.45 billion. www.exxonmobil.com
Kimberly-Clark Corp. (NYSE: KMB) announced that it plans to spin off its healthcare business into a stand-alone public company. The unit has approximately $1.6 billion in annual revenue and makes both surgical and infection prevention products and medical devices. www.kimberly-clark.com
Sigma Alimentos, a Mexican frozen foods company, has offered to acquire Spanish meat processorCampofrio Food Group (CATS: CFG) for €695 million. www.campofriofoodgroup.com
Telecom Italia (BIT: TIT) has agreed to sell its controlling stake in Telecom Argentina (BASE: TECO2) to Mexico’s Fintech Group for approximately $960 million. www.telecom.com.ar
CardioDx, a Palo Alto, Calif.-based provider of cardiovascular genomic diagnostics, has postponed its planned $86.25 million IPO. The company had planned to trade on the Nasdaq under ticker symbol CDX, with BoA Merrill Lynch and Jefferies serving as lead underwriters. It has raised over $110 million in VC funding, from Temasek Life Sciences (19.9% pre-IPO stake), Longitude Capital (17.9%), Artiman Ventures (13.9%), Kleiner Perkins Caufield & Byers (9.5%), J.P. Morgan (6.4%), Mohr Davidow Ventures (5.8%), TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, Acadia Woods Partners, Bright Capital and GE Capital. www.cardiodx.com
Celladon Corp., a La Jolla, Calif.-based cardiovascular drug developer, has postponed its planned $86.25 million IPO. The company had planned to trade on the Nasdaq under ticker symbol CLDN, with J.P. Morgan and Barclays serving as lead underwriters. The pre-revenue company has raised around $120 million in VC funding, from Enterprise Partners Venture Capital (15.1% pre-IPO stake), Pfizer Ventures (13.1%), Lundbeckfond Ventures (13%), Novartis Venture Funds (11.6%), Johnson & Johnson Development Corp. (10.1%), GBS Venture Partners (8.3%), Venrock (7.7%) and H&Q Healthcare Investors (7.3%). www.celladon.net
Zulily, a Seattle-based ecommerce company focused on clothing and products for babies and children, raised $263 million in its IPO. The company priced 11.5 million shares at $22 per share (above offering range), and has an initial market cap of around $2.68 billion. It will trade on the Nasdaq under ticker symbol ZU, while Goldman Sachs, BoA Merrill Lynch and Citigroup served as lead underwriters. It reports $2.4 million in net income on $272 million in revenue for the first half of 2013, compared to a $6 million net loss on $127 million in revenue for the year-earlier period. Zulily has raised nearly $140 million in VC funding from Maveron (23.5% pre-IPO stake), August Capital (7.4%) and Andreessen Horowitz (7.3%), Trinity Ventures (2.6%), Meritech Capital Partners (2.4%) and Greenspring Associates (1.6%). www.zulily.com
Sign up for Dan Primack’s daily email newsletter on deals and deal-makers: GetTermSheet.com
